Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

The US Food and Drug Administration (FDA) is cautioning patients and caregivers about the potential for not receiving blood ...

Shanghai's Ruijin Hospital announced today that researchers have developed a groundbreaking non-invasive blood glucose ...

Shanghai researchers have devised a revolutionary, non-invasive method to monitor blood glucose, allowing for accurate blood ...

Trinity Biotech ( ($TRIB) ) has shared an update. On February 6, 2025, Trinity Biotech announced significant improvements in its continuous ...

Trinity Biotech (TRIB) announced new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance ...

How does the body regulate the activity of insulin-producing cells in order to react quickly to changing conditions? Researchers have investigated this question.

Senseonics (NYSE:SENS) announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) ...

Devices and Getinge have recently announced their partnership under which they will integrate Getinge’s bioreactors with 908 ...

Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...